Previous 10 | Next 10 |
CytoSorbents ( NASDAQ: CTSO ) notifies that the U.S. Army Medical Research Acquisition Activity has awarded the company a three-year Phase III contract valued at $4,292,641 to enable freeze-dried universal plasma using its HemoDefend-BGA technology. Without the n...
CytoSorbents Awarded an Approximately $4.3M Contract by the U.S. Department of Defense to Develop HemoDefend-BGA™ for Freeze-Dried Universal Plasma PR Newswire PRINCETON, N.J. , Oct. 6, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:...
CytoSorbents to Present at the Dawson James Securities 2022 Small Cap Growth Conference PR Newswire PRINCETON, N.J. , Oct. 4, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in...
CytoSorbents Achieves ISO 13485 Certification of Princeton Manufacturing Facility in New Jersey PR Newswire CytoSorb®, DrugSorb®-ATR, and ECOS-300CY® now cleared for manufacturing from this site PRINCETON, N.J. , Sept. 27, 2022 /PRN...
CytoSorbents ( NASDAQ: CTSO ) said it received a two-year grant of ~$1.98M from the U.S. Department of Defense to help develop HemoDefend-BGA adsorber to a fully-finished commercial device which will be evaluated in a pre-clinical porcine study. The contract ...
The U.S. Department of Defense Awards CytoSorbents an Approximately $2.0M Contract to Support HemoDefend-BGA™ Development for Life-saving Universal Plasma PR Newswire PRINCETON, N.J. , Sept. 9, 2022 /PRNewswire/ -- CytoSorbents Corporation ...
CytoSorbents to Present at the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire PRINCETON, N.J. , Sept. 7, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions i...
The CytoSorbents ( NASDAQ: CTSO ) said the Turkish Ministry of Health approved national reimbursement for CytoSorb. CytoSorbents has a strategic collaboration with Bıçakcılar Medical Devices in Turkey. "Our partnership with Bıçak...
Turkish Ministry of Health Grants National Reimbursement to CytoSorb® PR Newswire The cost of treatment with CytoSorb ® will now be covered by the public sector in Turkey PRINCETON, N.J. , Aug. 23, 2022 /PRNewswire/ -- Cy...
CytoSorbents ( NASDAQ: CTSO ) said the Israeli Ministry of Health approved national reimbursement for CytoSorb in certain cardiac surgery indications which is expected to take effect in 2023. The company added that once the policy revision is completed, public hospital...
News, Short Squeeze, Breakout and More Instantly...
CytoSorbents Corporation Company Name:
CTSO Stock Symbol:
NASDAQ Market:
CytoSorbents Corporation Website:
PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces that it has regained comp...
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, is proud to announce the launch of ...
PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces it will present...